MHC Class I Antigens and Immune Surveillance in Transformed Cells
The DOI matches its Crossref record; 252 of the 256 references it cites were found in a registry or an index.
Abstract
MHC class I antigens play a crucial role in the interaction of tumor cells with the host immune system, in particular, in the presentation of peptides as tumor-associated antigens to cytotoxic lymphocytes (CTLs) and in the regulation of cytolytic activity of natural killer (NK) cells. In this review we discuss the role of MHC class I antigens in the recognition and elimination of transformed cells and in the generation of tumor immune escape routes when MHC class I losses occur in tumors. The different altered MHC class I phenotypes and their distribution in different human tumors are the main topic of this review. In addition, molecular defects that underlie MHC alterations in transformed cells are also described in detail. Future research directions in this field are also discussed, including the laboratory analysis of tumor MHC class I-negative variants and the possible restoration of MHC class I expression.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Previous work has reported loss of heterozygosity (LOH) of HLA-I genes in cancer (43, 44).”
From Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy (2018) · cites this paper as [43]
Citations
Cites
Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,816
Cancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
Structure of the human class I histocompatibility antigen, HLA-A2
Bjorkman, P. J., Saper, M. A., Samraoui, B., Bennett, W. S., Strominger, J. L., & Wiley, D. C. (1987) · Nature · doi:10.1038/329506a0 · Cited by 3,472
The Three Es of Cancer Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104803 · Cited by 3,072
Activation of NK Cells and T Cells by NKG2D, a Receptor for Stress-Inducible MICA
Bauer, S., Groh, V., Wu, J., Steinle, A., Phillips, J. H., Lanier, L. L., & Spies, T. (1999) · Science · doi:10.1126/science.285.5428.727 · Cited by 2,999
Lanier, L. L. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115526 · Cited by 2,769
In search of the ‘missing self’: MHC molecules and NK cell recognition
Ljunggren, H.-G., & Kärre, K. (1990) · Immunology Today · doi:10.1016/0167-5699(90)90097-s · Cited by 2,687
TGF-β Signaling in Tumor Suppression and Cancer Progression
Derynck, R., Akhurst, R. J., & Balmain, A. (2001) · Nature Genetics · doi:10.1038/ng1001-117 · Cited by 2,275
HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C
Braud, V. M., Allan, D. S. J., O'Callaghan, C. A., Söderström, K., D'Andrea, A., Ogg, G. S., Lazetic, S., Young, N. T., Bell, J. I., Phillips, J. H., et al. (1998) · Nature · doi:10.1038/35869 · Cited by 2,227
Immunosuppressive networks in the tumour environment and their therapeutic relevance
Zou, W. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1586 · Cited by 2,057
Activating Receptors and Coreceptors Involved in Human Natural Killer Cell-Mediated Cytolysis
Moretta, A., Bottino, C., Vitale, M., Pende, D., Cantoni, C., Mingari, M. C., Biassoni, R., & Moretta, L. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.197 · Cited by 1,778
Townsend, A. (1986) · Cell · doi:10.1016/0092-8674(86)90019-x · Cited by 1,699
MHC ligands and peptide motifs: first listing
Rammensee, H.-G., Friede, T., & Stevanović, S. (1995) · Immunogenetics · doi:10.1007/bf00172063 · Cited by 1,638
The 26S Proteasome: A Molecular Machine Designed for Controlled Proteolysis
Voges, D., Zwickl, P., & Baumeister, W. (1999) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.68.1.1015 · Cited by 1,608
Rapid degradation of a large fraction of newly synthesized proteins by proteasomes
Schubert, U., Antón, L. C., Gibbs, J., Norbury, C. C., Yewdell, J. W., & Bennink, J. R. (2000) · Nature · doi:10.1038/35008096 · Cited by 1,536
Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice
Kaplan, D. H., Shankaran, V., Dighe, A. S., Stockert, E., Aguet, M., Old, L. J., & Schreiber, R. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.13.7556 · Cited by 1,465
Melanoma Cell Expression of Fas(Apo-1/CD95) Ligand: Implications for Tumor Immune Escape
Hahne, M., Rimoldi, D., Schröter, M., Romero, P., Schreier, M., French, L. E., Schneider, P., Bornand, T., Fontana, A., Lienard, D., et al. (1996) · Science · doi:10.1126/science.274.5291.1363 · Cited by 1,249
Immunity to Methylcholanthrene-Induced Sarcomas
(1957) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/18.6.769 · Cited by 1,229
Marincola, F. M., Jaffee, E. M., Hicklin, D. J., & Ferrone, S. (1999) · Advances in Immunology · doi:10.1016/s0065-2776(08)60911-6 · Cited by 1,174
CELL BIOLOGY OF ANTIGEN PROCESSING IN VITRO AND IN VIVO
Trombetta, E. S., & Mellman, I. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104538 · Cited by 1,173
A p16 INK4a -Insensitive CDK4 Mutant Targeted by Cytolytic T Lymphocytes in a Human Melanoma
Wölfel, T., Hauer, M., Schneider, J., Serrano, M., Wölfel, C., Klehmann-Hieb, E., De Plaen, E., Hankeln, T., Meyer zum Büschenfelde, K.-H., & Beach, D. (1995) · Science · doi:10.1126/science.7652577 · Cited by 1,154
Proteolysis: from the lysosome to ubiquitin and the proteasome
Ciechanover, A. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1552 · Cited by 1,133
Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity
Diefenbach, A., Jensen, E. R., Jamieson, A. M., & Raulet, D. H. (2001) · Nature · doi:10.1038/35093109 · Cited by 1,083
Human Diversity in Killer Cell Inhibitory Receptor Genes
Uhrberg, M., Valiante, N. M., Shum, B. P., Shilling, H. G., Lienert-Weidenbach, K., Corliss, B., Tyan, D., Lanier, L. L., & Parham, P. (1997) · Immunity · doi:10.1016/s1074-7613(00)80394-5 · Cited by 1,059
Natural selection of tumor variants in the generation of “tumor escape” phenotypes
Khong, H. T., & Restifo, N. P. (2002) · Nature Immunology · doi:10.1038/ni1102-999 · Cited by 1,058
Gabrilovich, D., Ishida, T., Oyama, T., Ran, S., Kravtsov, V., Nadaf, S., & Carbone, D. P. (1998) · Blood · doi:10.1182/blood.v92.11.4150 · Cited by 1,048
Groh, V, Bahram, S., Bauer, S., Herman, A., Beauchamp, M., & Spies, T. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.22.12445 · Cited by 1,017
MECHANISMS OF MHC CLASS I–RESTRICTED ANTIGEN PROCESSING
Pamer, E., & Cresswell, P. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.323 · Cited by 1,008
Brichard, V, Van Pel, A., Wölfel, T., Wölfel, C., De Plaen, E., Lethé, B., Coulie, P., & Boon, T. (1993) · The Journal of experimental medicine · doi:10.1084/jem.178.2.489 · Cited by 950
DEGRADATION OF CELL PROTEINS AND THE GENERATION OF MHC CLASS I-PRESENTED PEPTIDES
Rock, K. L., & Goldberg, A. L. (1999) · Annual Review of Immunology · doi:10.1146/annurev.immunol.17.1.739 · Cited by 921
Kawakami, Y., Eliyahu, S., Sakaguchi, K., Robbins, P. F., Rivoltini, L., Yannelli, J. R., Appella, E., & Rosenberg, S. A. (1994) · The Journal of experimental medicine · doi:10.1084/jem.180.1.347 · Cited by 862
Human tumor antigens recognized by T lymphocytes.
Boon, T., & van der Bruggen, P. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.3.725 · Cited by 842
Cancer--A Biological Approach: I. The Processes Of Control. II. The Significance of Somatic Mutation
Burnet, M. (1957) · BMJ · doi:10.1136/bmj.1.5022.779 · Cited by 810
Implications for immunosurveillance of altered HLA class I phenotypes in human tumours
Garrido, F., Ruiz-Cabello, F., Cabrera, T., Pérez-Villar, J. J., López-Botet, M., Duggan-Keen, M., & Stern, P. L. (1997) · Immunology Today · doi:10.1016/s0167-5699(96)10075-x · Cited by 770
Self-citationIkeda, H., Lethé, B., Lehmann, F., Van Baren, N., Baurain, J.-F., De Smet, C., Chambost, H., Vitale, M., Moretta, A., Boon, T., et al. (1997) · Immunity · doi:10.1016/s1074-7613(00)80426-4 · Cited by 762
Does the Immune System See Tumors as Foreign or Self?
Pardoll, D. (2003) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141135 · Cited by 753
Kaer, L. V., Ashton-Rickardt, P. G., Ploegh, H. L., & Tonegawa, S. (1992) · Cell · doi:10.1016/s0092-8674(05)80068-6 · Cited by 724
Role of MHC Gene Products in Immune Regulation
Benacerraf, B. (1981) · Science · doi:10.1126/science.6165083 · Cited by 696
A listing of human tumor antigens recognized by T cells
Renkvist, N., Castelli, C., Robbins, P. F., & Parmiani, G. (2001) · Cancer Immunology, Immunotherapy · doi:10.1007/s002620000169 · Cited by 694
Antigenic properties of methylcholanthrene-induced tumors in mice of the strain of origin.
Ej, F. (1953) · PubMed · Cited by 690
HUMAN T CELL RESPONSES AGAINST MELANOMA
Boon, T., Coulie, P. G., Eynde, B. J. V. D., & Bruggen, P. V. D. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.24.021605.090733 · Cited by 651
Antigen processing by the proteasome
Kloetzel, P.-M. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35056572 · Cited by 637
Van den Eynde, B. J., & van der Bruggen, P. (1997) · Current Opinion in Immunology · doi:10.1016/s0952-7915(97)80050-7 · Cited by 623
Bakker, A. B., Schreurs, M. W., de Boer, A. J., Kawakami, Y., Rosenberg, S. A., Adema, G. J., & Figdor, C. G. (1994) · The Journal of experimental medicine · doi:10.1084/jem.179.3.1005 · Cited by 589
An overview of the MAGE gene family with the identification of all human members of the family.
Chomez, P., Backer, O. D., Bertrand, M. J. M., Plaen, E. D., Boon, T., & Lucas, S. (2001) · PubMed · Cited by 573
Robbins, P. F., El-Gamil, M., Li, Y. F., Kawakami, Y., Loftus, D., Appella, E., & Rosenberg, S. A. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.3.1185 · Cited by 550
Restifo, N. P., Marincola, F. M., Kawakami, Y., Taubenberger, J., Yannelli, J. R., & Rosenberg, S. A. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.2.100 · Cited by 533
MHC Class I Expression in Mice Lacking the Proteasome Subunit LMP-7
Fehling, H. J., Swat, W., Laplace, C., Kühn, R., Rajewsky, K., Müller, U., & von Boehmer, H. (1994) · Science · doi:10.1126/science.8066463 · Cited by 525
A binding site for the T-cell co-receptor CD8 on the α3 domain of HLA-A2
Salter, R. D., Benjamin, R. J., Wesley, P. K., Buxton, S. E., Garrett, T. P. J., Clayberger, C., Krensky, A. M., Norment, A. M., Littman, D. R., & Parham, P. (1990) · Nature · doi:10.1038/345041a0 · Cited by 520
MHC class I antigens, immune surveillance, and tumor immune escape
Garcia‐Lora, A., Algarra, I., & Garrido, F. (2003) · Journal of Cellular Physiology · doi:10.1002/jcp.10290 · Cited by 501
Self-citationHLA-A2 molecules in an antigen-processing mutant cell contain signal sequence-derived peptides
Wei, M. L., & Cresswell, P. (1992) · Nature · doi:10.1038/356443a0 · Cited by 496
Antigen-processing machinery breakdown and tumor growth
Seliger, B., Maeurer, M. J., & Ferrone, S. (2000) · Immunology Today · doi:10.1016/s0167-5699(00)01692-3 · Cited by 459
Immune surveillance against a solid tumor fails because of immunological ignorance
Ochsenbein, A. F., Klenerman, P., Karrer, U., Ludewig, B., Pericin, M., Hengartner, H., & Zinkernagel, R. M. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.5.2233 · Cited by 453
Diefenbach, A., Tomasello, E., Lucas, M., Jamieson, A. M., Hsia, J. K., Vivier, E., & Raulet, D. H. (2002) · Nature Immunology · doi:10.1038/ni858 · Cited by 452
Cross‐presentation: underlying mechanisms and role in immune surveillance
Rock, K. L., & Shen, L. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00301.x · Cited by 451
Natural history of HLA expression during tumour development
Garrido, F., Cabrera, T., Concha, A., Glew, S., Ruiz-Cabello, F., & Stern, P. L. (1993) · Immunology Today · doi:10.1016/0167-5699(93)90264-l · Cited by 448
Self-citationMaking sense of mass destruction: quantitating MHC class I antigen presentation
Yewdell, J. W., Reits, E., & Neefjes, J. (2003) · Nature Reviews Immunology · doi:10.1038/nri1250 · Cited by 445
Immunoproteasome Assembly: Cooperative Incorporation of Interferon γ (IFN-γ)–inducible Subunits
Griffin, T. A., Nandi, D., Cruz, M., Fehling, H. J., Kaer, L. V., Monaco, J. J., & Colbert, R. A. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.1.97 · Cited by 444
Hsu, K. C., Chida, S., Geraghty, D. E., & Dupont, B. (2002) · Immunological Reviews · doi:10.1034/j.1600-065x.2002.19004.x · Cited by 443
NKG2D recruits two distinct adapters to trigger NK cell activation and costimulation
Gilfillan, S., Ho, E. L., Cella, M., Yokoyama, W. M., & Colonna, M. (2002) · Nature Immunology · doi:10.1038/ni857 · Cited by 437
Mechanisms of MHC class I‐restricted antigen processing and cross‐presentation
Cresswell, P., Ackerman, A. L., Giodini, A., Peaper, D. R., & Wearsch, P. A. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00316.x · Cited by 435
Killer immunoglobulin-like receptors
Moretta, L., & Moretta, A. (2004) · Current Opinion in Immunology · doi:10.1016/j.coi.2004.07.010 · Cited by 409
THE DETAILED DISTRIBUTION OF HLA-A, B, C ANTIGENS IN NORMAL HUMAN ORGANS
DAAR, A. S., FUGGLE, S. V., FABRE, J. W., TING, A., & MORRIS, P. J. (1984) · Transplantation · doi:10.1097/00007890-198409000-00018 · Cited by 406
Wallich, R., Bulbuc, N., Hämmerling, G. J., Katzav, S., Segal, S., & Feldman, M. (1985) · Nature · doi:10.1038/315301a0 · Cited by 402
Reversal of Oncogenesis by the Expression of a Major Histocompatibility Complex Class I Gene
Tanaka, K., Isselbacher, K. J., Khoury, G., & Jay, G. (1985) · Science · doi:10.1126/science.3975631 · Cited by 366
Navarro, F., Llano, M., Bellón, T., Colonna, M., Geraghty, D. E., & López-Botet, M. (1999) · European Journal of Immunology · doi:10.1002/(sici)1521-4141(199901)29:01<277::aid-immu277>3.0.co;2-4 · Cited by 366
Intradermal Immunization of C3H Mice against a Sarcoma That Originated in an Animal of the Same Line
Gross, L. (1943) · Cancer Research · Cited by 360
Immunoreceptor tyrosine-based inhibition motifs
Vivier, E., & Daëron, M. (1997) · Immunology Today · doi:10.1016/s0167-5699(97)80025-4 · Cited by 351
The host—tumor immune conflict: from immunosuppression to resistance and destruction
Chouaib, S., Asselin-Paturel, C., Mami-Chouaib, F., Caignard, A., & Blay, J. Y. (1997) · Immunology Today · doi:10.1016/s0167-5699(97)01115-8 · Cited by 350
Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues
Jungbluth, A. A., Chen, Y.-T., Stockert, E., Busam, K. J., Kolb, D., Iversen, K., Coplan, K., Williamson, B., Altorki, N., & Old, L. J. (2001) · International Journal of Cancer · doi:10.1002/ijc.1282 · Cited by 347
Rejection of transplantable AKR leukaemia cells following MHC DNA-mediated cell transformation
Hui, K., Grosveld, F., & Festenstein, H. (1984) · Nature · doi:10.1038/311750a0 · Cited by 341
A CASP-8 Mutation Recognized by Cytolytic T Lymphocytes on a Human Head and Neck Carcinoma
Mandruzzato, S., Brasseur, F., Andry, G., Boon, T., & Bruggen, P. V. D. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.5.785 · Cited by 321
The genetic and antigenic basis of tumour transplantation
Gorer, P. A. (1937) · The Journal of Pathology and Bacteriology · doi:10.1002/path.1700440313 · Cited by 313
D'Urso, C. M., Wang, Z. G., Cao, Y., Tatake, R., Zeff, R. A., & Ferrone, S. (1991) · Journal of Clinical Investigation · doi:10.1172/jci114984 · Cited by 309
MHC antigens and tumor escape from immune surveillance
(2001) · Advances in Cancer Research · doi:10.1016/s0065-230x(01)83005-0 · Cited by 305
Self-citationDraenert, R., Le Gall, S., Pfafferott, K. J., Leslie, A. J., Chetty, P., Brander, C., Holmes, E. C., Chang, S.-C., Feeney, M. E., Addo, M. M., et al. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20031982 · Cited by 304
Neumann, H., Schmidt, H., Cavalié, A., Jenne, D., & Wekerle, H. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.185.2.305 · Cited by 288
IFN-γ-induced immune adaptation of the proteasome system is an accelerated and transient response
Heink, S., Ludwig, D., Kloetzel, P.-M., & Krüger, E. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501711102 · Cited by 288
The discovery of MHC restriction
Zinkernagel, R. M., & Doherty, P. C. (1997) · Immunology Today · doi:10.1016/s0167-5699(97)80008-4 · Cited by 287
Koopman, L. A., Corver, W. E., van der Slik, A. R., Giphart, M. J., & Fleuren, G. J. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.6.961 · Cited by 279
HLA class I antigen abnormalities and immune escape by malignant cells
Seliger, B., Cabrera, T., Garrido, F., & Ferrone, S. (2002) · Seminars in Cancer Biology · doi:10.1006/scbi.2001.0404 · Cited by 270
Self-citationMeissner, M., Reichert, T. E., Kunkel, M., Gooding, W., Whiteside, T. L., Ferrone, S., & Seliger, B. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2146 · Cited by 266
Watson, N. F. S., Ramage, J. M., Madjd, Z., Spendlove, I., Ellis, I. O., Scholefield, J. H., & Durrant, L. G. (2006) · International Journal of Cancer · doi:10.1002/ijc.21303 · Cited by 254
Nabel, G. J., Gordon, D., Bishop, D. K., Nickoloff, B. J., Yang, Z.-Y., Aruga, A., Cameron, M. J., Nabel, E. G., & Chang, A. E. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.26.15388 · Cited by 239
Serrano, A., Tanzarella, S., Lionello, I., Mendez, R., Traversari, C., Ruiz-Cabello, F., & Garrido, F. (2001) · International Journal of Cancer · doi:10.1002/ijc.1452 · Cited by 239
Self-citationGenes of the Major Histocompatibility Complex in Mouse and Man
Steinmetz, M., & Hood, L. (1983) · Science · doi:10.1126/science.6356354 · Cited by 238
Reversal of natural killing susceptibility in target cells expressing transfected class I HLA genes.
Storkus, W. J., Alexander, J., Payne, J. A., Dawson, J. R., & Cresswell, P. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.7.2361 · Cited by 236
Strehl, B., Seifert, U., Krüger, E., Heink, S., Kuckelkorn, U., & Kloetzel, P. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00308.x · Cited by 234
The enigma of the natural killer cell
Gumperz, J. E., & Parham, P. (1995) · Nature · doi:10.1038/378245a0 · Cited by 232
Höftberger, R., Aboul‐Enein, F., Brueck, W., Lucchinetti, C., Rodriguez, M., Schmidbauer, M., Jellinger, K., & Lassmann, H. (2004) · Brain Pathology · doi:10.1111/j.1750-3639.2004.tb00496.x · Cited by 229
The innate immune response to tumors and its role in the induction of T‐cell immunity
Diefenbach, A., & Raulet, D. H. (2002) · Immunological Reviews · doi:10.1034/j.1600-065x.2002.18802.x · Cited by 228
Differential expression of HLA-E, HLA-F, and HLA-G transcripts in human tissue
Wei, X., & Orr, H. T. (1990) · Human Immunology · doi:10.1016/0198-8859(90)90076-2 · Cited by 225
Lehmann, F., Marchand, M., Hainaut, P., Pouillart, P., Sastre, X., Ikeda, H., Boon, T., & Coulie, P. G. (1995) · European Journal of Immunology · doi:10.1002/eji.1830250206 · Cited by 225
Neefjes, J. J., & Ploegh, H. L. (1988) · European Journal of Immunology · doi:10.1002/eji.1830180522 · Cited by 223
Class 1 major histocompatibility complex antigens on human extra-villous trophoblast.
Redman, C., McMichael, A. J., Stirrat, G. M., Sunderland, C. A., & Ting, A. (1984) · PubMed Central · Cited by 222
Functions of nonclassical MHC and non-MHC-encoded class I molecules
Braud, V. M., Allan, D. S., & McMichael, A. J. (1999) · Current Opinion in Immunology · doi:10.1016/s0952-7915(99)80018-1 · Cited by 217
Garbi, N., Tanaka, S., Momburg, F., & Hämmerling, G. J. (2006) · Nature Immunology · doi:10.1038/ni1288 · Cited by 216
Bachmann, M. F., Barner, M., Viola, A., & Kopf, M. (1999) · European Journal of Immunology · doi:10.1002/(sici)1521-4141(199901)29:01<291::aid-immu291>3.0.co;2-k · Cited by 204
Chen, H. L., Gabrilovich, D., Tampé, R., Girgis, K. R., Nadaf, S., & Carbone, D. P. (1996) · Nature Genetics · doi:10.1038/ng0696-210 · Cited by 203
Nie, Y. (2001) · Carcinogenesis · doi:10.1093/carcin/22.10.1615 · Cited by 202
beta2-Microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma.
Hicklin, D. J., Wang, Z., Arienti, F., Rivoltini, L., Parmiani, G., & Ferrone, S. (1998) · Journal of Clinical Investigation · doi:10.1172/jci498 · Cited by 198
The Major Histocompatibility System in Man and Animals
(1977) · Springer eBooks · doi:10.1007/978-3-642-95293-7 · Cited by 193
Seliger, B., Ritz, U., Abele, R., Bock, M., Tampé, R., Sutter, G., Drexler, I., Huber, C., & Ferrone, S. (2001) · PubMed · Cited by 189
Variable receptors controlling activation and inhibition of NK cells
McQueen, K. L., & Parham, P. (2002) · Current Opinion in Immunology · doi:10.1016/s0952-7915(02)00380-1 · Cited by 186
Analysis of HLA-E expression in human tumors
Marín, R., Ruiz-Cabello, F., Pedrinaci, S., Méndez, R., Jiménez, P., Geraghty, D. E., & Garrido, F. (2003) · Immunogenetics · doi:10.1007/s00251-002-0526-9 · Cited by 178
Self-citationKloor, M., Becker, C., Benner, A., Woerner, S. M., Gebert, J., Ferrone, S., & von Knebel Doeberitz, M. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0044 · Cited by 178
The functionality of HLA‐G is emerging
Le Bouteiller, P., & Blaschitz, A. (1999) · Immunological Reviews · doi:10.1111/j.1600-065x.1999.tb01396.x · Cited by 177
Johnsen, A. K., Templeton, D. J., Sy, M.-S., & Harding, C. V. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.8.4224 · Cited by 173
Schubert, I., & Wobus, U. (2000) · Nature · doi:10.1038/35004754 · Cited by 170
Natali, P. G., Bigotti, A., Nicotra, M., Viora, M., Manfredi, D., & Ferrone, S. (1984) · PubMed · Cited by 169
Browning, M. J., Krausa, P., Rowan, A., Bicknell, D. C., Bodmer, J. G., & Bodmer, W. F. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.7.2842 · Cited by 167
Cabrera, C. M., Jiménez, P., Cabrera, T., Esparza, C., Ruiz‐Cabello, F., & Garrido, F. (2003) · Tissue Antigens · doi:10.1034/j.1399-0039.2003.00020.x · Cited by 164
Self-citationAntigenic Tumor Cell Variants Obtained with Mutagens
(1983) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)61034-9 · Cited by 163
Variation Within the Human Killer Cell Immunoglobulin-Like Receptor ( KIR) Gene Family
Yawata, M., Yawata, N., Abi-Rached, L., & Parham, P. (2002) · Critical Reviews™ in Immunology · doi:10.1615/critrevimmunol.v22.i5-6.70 · Cited by 162
Wischhusen, J., Friese, M. A., Mittelbronn, M. G. A., Meyermann, R., & Weller, M. (2005) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/64.6.523 · Cited by 157
Multiple roles of mucins in pancreatic cancer, a lethal and challenging malignancy
Moniaux, N., Andrianifahanana, M., Brand, R. E., & Batra, S. K. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602163 · Cited by 156
Tumor-induced death of immune cells: its mechanisms and consequences
Whiteside, T. L. (2002) · Seminars in Cancer Biology · doi:10.1006/scbi.2001.0402 · Cited by 151
Alterations of Fas (Apo-1/CD95) Gene in Cutaneous Malignant Melanoma
Shin, M. S., Park, W. S., Kim, S., Kim, H. S., Kang, S. J., Song, K. Y., Park, J. Y., Dong, S. M., Pi, J. H., Oh, R. R., et al. (1999) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)65434-x · Cited by 149
Garrido, F., FESTENSTEIN, H., & Schirrmacher, V. (1976) · Nature · doi:10.1038/261705a0 · Cited by 149
Self-citationBenitez, R., Godelaine, D., Lopez‐Nevot, M. A., Brasseur, F., Jimenez, P., Marchand, M., Oliva, M. R., van Baren, N., Cabrera, T., Andry, G., et al. (1998) · Tissue Antigens · doi:10.1111/j.1399-0039.1998.tb03082.x · Cited by 149
Self-citationTotal loss of MHC class I is an independent indicator of good prognosis in breast cancer
Madjd, Z., Spendlove, I., Pinder, S. E., Ellis, I. O., & Durrant, L. G. (2005) · International Journal of Cancer · doi:10.1002/ijc.21163 · Cited by 149
HLA class I antigen loss, tumor immune escape and immune selection
Campoli, M. R., Chang, C., & Ferrone, S. (2002) · Vaccine · doi:10.1016/s0264-410x(02)00386-9 · Cited by 148
Hla Class I Antigens in Human Tumors
Garrido, F., Cabrera, T., López‐Nevot, M. Á., & Ruiz‐Cabello, F. (1995) · Advances in cancer research · doi:10.1016/s0065-230x(08)60713-7 · Cited by 147
Self-citationSearch for common antigenicities among twenty-five sarcomas induced by methylcholanthrene.
Basombrio, M. A. (1970) · PubMed · Cited by 147
Romero, J. M., Jiménez, P., Cabrera, T., Cózar, J. M., Pedrinaci, S., Tallada, M., Garrido, F., & Ruiz-Cabello, F. (2005) · International Journal of Cancer · doi:10.1002/ijc.20499 · Cited by 140
Self-citationOrganization of plasma membrane functional rafts upon T cell activation
Tuosto, L., Parolini, I., Schröder, S., Sargiacomo, M., Lanzavecchia, A., & Viola, A. (2001) · European Journal of Immunology · doi:10.1002/1521-4141(200102)31:2<345::aid-immu345>3.0.co;2-l · Cited by 138
Immunodominance and tumor escape
Schreiber, H. W., Wu, T. H., Nachman, J. B., & Kast, W. M. (2002) · Seminars in Cancer Biology · doi:10.1006/scbi.2001.0401 · Cited by 135
The Major Histocompatibility System in Man and Animals.
(1979) · Annals of Internal Medicine · doi:10.7326/0003-4819-91-1-147_3 · Cited by 134
Sivori, S., Parolini, S., Marcenaro, E., Castriconi, R., Pende, D., Millo, R., & Moretta, A. (2000) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(00)00221-6 · Cited by 132
HLA Class I Chromosomal Region, Genes, and Products: Facts and Questions
Bouteiller, P. P. L. (2017) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.v37.i2-6.80 · Cited by 131
The Detection of Antigenic Differences in Mouse Erythrocytes by the Employment of Immune Sera
Gorer, P. A. (1936) · PubMed Central · Cited by 130
HLA Class I Chromosomal Region, Genes, and Products: Facts and Questions
Bouteiller, P. P. L. (1994) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.v14.i2.10 · Cited by 130
Multiple mechanisms underlie HLA dysregulation in cervical cancer
Brady, C. S., Bartholomew, J. S., Burt, D. J., Duggan-Keen, M. F., Glenville, S., Telford, N., Little, A., Davidson, J. A., Jiménez, P., Ruiz‐Cabello, F., et al. (2000) · Tissue Antigens · doi:10.1034/j.1399-0039.2000.550502.x · Cited by 128
Self-citationHigh frequency of altered HLA class I phenotypes in invasive breast carcinomas
Cabrera, T., Fernandez, M. A., Sierra, À., Garrido, A., Herruzo, A., Escobedo, A., Fabra, À., & Garrido, F. (1996) · Human Immunology · doi:10.1016/0198-8859(96)00145-0 · Cited by 126
Self-citationLee, K.-H., Panelli, M. C., Kim, C. J., Riker, A. I., Bettinotti, M. P., Roden, M. M., Fetsch, P., Abati, A., Rosenberg, S. A., & Marincola, F. M. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.8.4183 · Cited by 124
Smith, M. E., Marsh, S. G., Bodmer, J. G., Gelsthorpe, K., & Bodmer, W. F. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.14.5557 · Cited by 122
Maleno, I., López‐Nevot, M. Á., Cabrera, T., Jose, S., & Garrido, F. (2002) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-002-0296-0 · Cited by 122
Self-citationTumour immunology: MHC antigens and malignancy
FESTENSTEIN, H., & Garrido, F. (1986) · Nature · doi:10.1038/322502a0 · Cited by 121
Self-citationAnalysis of HLA expression in human tumor tissues
Cabrera, T., López‐Nevot, M. Á., Gaforio, J. J., Ruiz‐Cabello, F., & Garrido, F. (2003) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-002-0332-0 · Cited by 119
Self-citationHarris, M. R., Yu, Y. Y. L., Kindle, C. S., Hansen, T. H., & Solheim, J. C. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.11.5404 · Cited by 118
Chromosome loss is the most frequent mechanism contributing to HLA haplotype loss in human tumors
Jim�nez, P., Cant�n, J., Collado, A., Cabrera, T., Serrano, A., Real, L. M., Garc�a, A., Ruiz-Cabello, F., & Garrido, F. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19990924)83:1<91::aid-ijc17>3.0.co;2-4 · Cited by 115
CD4 T Lymphocytes: A Critical Component of Antitumor Immunity
Ostrand‐Rosenberg, S. (2005) · Cancer Investigation · doi:10.1081/cnv-200067428 · Cited by 113
Vitale, M., Pelusi, G., Taroni, B., Gobbi, G., Micheloni, C., Rezzani, R., Donato, F., Wang, X., & Ferrone, S. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.67.11.1 · Cited by 113
High frequency of altered HLA class I phenotypes in invasive colorectal carcinomas
Cabrera, T., Collado, A., Fernandez, M. A., Ferron, A., Sancho, J., Ruiz‐Cabello, F., & Garrido, F. (1998) · Tissue Antigens · doi:10.1111/j.1399-0039.1998.tb02274.x · Cited by 111
Self-citationRitz, U., Momburg, F., Pilch, H., Huber, C., Maeurer, M., & Seliger, B. (2001) · International Journal of Oncology · doi:10.3892/ijo.19.6.1211 · Cited by 111
The role of the proteasome activator PA28 in MHC class I antigen processing
Sijts, A. J. A. M., Sun, Y., Janek, K., Kral, S., Paschen, A., Schadendorf, D., & Kloetzel, P. (2002) · Molecular Immunology · doi:10.1016/s0161-5890(02)00099-8 · Cited by 110
Petersson, M., Charo, J., Salazar-Onfray, F., Noffz, G., Mohaupt, M., Qin, Z., Klein, G., Blankenstein, T., & Kiessling, R. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.5.2099 · Cited by 109
Loss of interferon-gamma inducibility of TAP1 and LMP2 in a renal cell carcinoma cell line.
Dovhey, S. E., Ghosh, N., & Wright, K. L. (2000) · PubMed · Cited by 109
Effect ofmts1 (S100A4) expression on the progression of human breast cancer cells
Grigorian, M., Ambartsumian, N. S., Lykkesfeldt, A. E., Bastholm, L., Elling, F., Georgiev, G. P., & Lukanidin, E. M. (1996) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19960917)67:6<816::aid-ijc10>3.0.co;2-# · Cited by 108
Maleno, I., Cabrera, C., Cabrera, T., Paco, L., López‐Nevot, M. Á., Collado, A., Ferr�n, A., & Garrido, F. (2004) · Immunogenetics · doi:10.1007/s00251-004-0692-z · Cited by 106
Self-citationLou, Y., Vitalis, T. Z., Basha, G., Cai, B., Chen, S. S., Choi, K. B., Jeffries, A. P., Elliott, W. M., Atkins, D., Seliger, B., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3977 · Cited by 104
Baurain, J., Colau, D., van Baren, N., Landry, C., Martelange, V., Vikkula, M., Boon, T., & Coulie, P. G. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.11.6057 · Cited by 101
Aberrant DNA methylation in cancer: potential clinical interventions
Strathdee, G., & Brown, R. (2002) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399402004222 · Cited by 101
Mechanisms of loss of HLA class I expression on colorectal tumor cells
Browning, M. J., Petronzelli, F., Bicknell, D. C., Krausa, P., Rowan, A., Tonks, S., Murray, N., Bodmer, J. G., & Bodmer, W. F. (1996) · Tissue Antigens · doi:10.1111/j.1399-0039.1996.tb02571.x · Cited by 101
Feenstra, M., Veltkamp, M., Van Kuik, J., Wiertsema, S., Slootweg, P., Van Den Tweel, J., De Weger, R., & Tilanus, M. (1999) · Tissue Antigens · doi:10.1034/j.1399-0039.1999.540304.x · Cited by 98
HLA class I recognition by killer cell Ig-like receptors.
Long, E. O., & Rajagopalan, S. (2000) · Seminars in Immunology · doi:10.1006/smim.2000.0212 · Cited by 97
Paschen, A., Méndez, R., Jimenez, P., Sucker, A., Ruiz‐Cabello, F., Song, M., Garrido, F., & Schadendorf, D. (2002) · International Journal of Cancer · doi:10.1002/ijc.10906 · Cited by 97
Self-citationKaklamanis, L., Townsend, A., Doussis-Anagnostopoulou, I. A., Mortensen, N. J. M., Harris, A. L., & Gatter, K. C. (1994) · PubMed Central · Cited by 97
Sequential Immune Escape and Shifting of T Cell Responses in a Long-Term Survivor of Melanoma
Yamshchikov, G. V., Mullins, D. W., Chang, C.-C., Ogino, T., Thompson, L., Presley, J., Galavotti, H., Aquila, W., Deacon, D., Ross, W., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.11.6863 · Cited by 95
Chang, C.-C., Campoli, M., Restifo, N. P., Wang, X., & Ferrone, S. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.3.1462 · Cited by 95
Burley, S. K. (1996) · Current Opinion in Structural Biology · doi:10.1016/s0959-440x(96)80097-2 · Cited by 92
Allelic Differences in the Relationship Between Proteasome Activity and MHC Class I Peptide Loading
Benham, A. M., Grommé, M., & Neefjes, J. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.1.83 · Cited by 86
Tumor cell recognition by natural killer cells.
Long, E. O. (2002) · Seminars in Cancer Biology · doi:10.1006/scbi.2001.0398 · Cited by 86
Immunoselection by T lymphocytes generates repeated MHC class I-deficient metastatic tumor variants
Garcia-Lora, A. M., Algarra, I., Gaforio, J. J., Ruiz‐Cabello, F., & Garrido, F. (2000) · International Journal of Cancer · doi:10.1002/1097-0215(20010101)91:1<109::aid-ijc1017>3.0.co;2-e · Cited by 85
Self-citationStructure of the HLA class I region and expression of its resident genes
Geraghty, D. E. (1993) · Current Opinion in Immunology · doi:10.1016/0952-7915(93)90073-2 · Cited by 84
Sequence organisation of the class II region of the human MHC
Beck, S., & Trowsdale, J. (1999) · Immunological Reviews · doi:10.1111/j.1600-065x.1999.tb01393.x · Cited by 84
Evolution and Function of the Major Histocompatibility System: Facts and Speculations
Klein, J. (1977) · Springer eBooks · doi:10.1007/978-3-642-95293-7_11 · Cited by 84
Cabrera, T., Lara, E., Romero, J. M., Maleno, I., Real, L. M., Ruiz‐Cabello, F., Valero, P. M., Camacho, F. M., & Garrido, F. (2006) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-006-0226-7 · Cited by 83
Self-citationLoss of an HLA haplotype in pancreas cancer tissue and its corresponding tumor derived cell line
Torres, M. J., Ruiz‐Cabello, F., Skoudy, A., Berrozpe, G., Jimenez, P., Serrano, A., Real, F. X., & Garrido, F. (1996) · Tissue Antigens · doi:10.1111/j.1399-0039.1996.tb02572.x · Cited by 83
Self-citationTAP1 down-regulation in primary melanoma lesions: An independent marker of poor prognosis
Kamarashev, J. A., Ferrone, S., Seifert, B., B�ni, R., Nestle, F. O., Burg, G., & Dummer, R. (2001) · International Journal of Cancer · doi:10.1002/1097-0215(20010120)95:1<73::aid-ijc1013>3.0.co;2-s · Cited by 79
MHC class I alleles and their exploration of the antigen‐processing machinery
Groothuis, T. A., Griekspoor, A., Neijssen, J., Herberts, C. A., & Neefjes, J. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00305.x · Cited by 76
Naumova, E. J., Mihaylova, A., Stoitchkov, K., Ivanova, M., Quin, L., & Toneva, M. (2004) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-004-0575-z · Cited by 76
Redondo, M., Concha, Á., Oldiviela, R., Cueto, A., Gonzalez, A., Garrido, F., & Ruiz‐Cabello, F. (1991) · PubMed · Cited by 75
Self-citationTumor aggressiveness and MHC class I and II antigens in laryngeal and breast cancer.
Concha, Á., Esteban, F., Cabrera, T., Ruiz‐Cabello, F., & Garrido, F. (1991) · PubMed · Cited by 75
Self-citationEpigenetic targets for immune intervention in human malignancies
Maio, M., Coral, S., Fratta, E., Altomonte, M., & Sigalotti, L. (2003) · Oncogene · doi:10.1038/sj.onc.1206956 · Cited by 74
HLA-DR expression is associated with excellent prognosis in squamous cell carcinoma of the larynx
Esteban, F., Ruiz‐Cabello, F., Concha, Á., Perez‐Ayala, M., Sánchez-Rozas, J. A., & Garrido, F. (1990) · Clinical & Experimental Metastasis · doi:10.1007/bf01810678 · Cited by 72
Self-citationImmunological ignorance of solid tumors
Ochsenbein, A. F. (2005) · Springer Seminars in Immunopathology · doi:10.1007/s00281-004-0192-0 · Cited by 70
Saveanu, L., Carroll, O., Hassainya, Y., & Endert, P. V. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00313.x · Cited by 69
Campoli, M. R., Ferrone, S., Zea, A. H., Rodríguez, P. C., & Ochoa, A. C. (2007) · Springer eBooks · doi:10.1007/0-387-27545-2_3 · Cited by 68
EXPRESSION OF CLASS I TRANSPLANTATION ANTIGENS
Harris, H. W., & Gill, T. J. (1986) · Transplantation · doi:10.1097/00007890-198608000-00001 · Cited by 66
Blanchet, O., Bourge, J. F., Zinszner, H., Israël, A., Kourilsky, P., Dausset, J. B., Degos, L., & Paul, P. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.8.3488 · Cited by 66
HLA class I defects in malignant lesions: What have we learned?
Chang, C., Campoli, M. R., & Ferrone, S. (2003) · The Keio Journal of Medicine · doi:10.2302/kjm.52.220 · Cited by 65
Structural and functional analysis of β2 microglobulin abnormalities in human lung and breast cancer
Chen, H. L., Gabrilovich, D. I., Virmani, A. K., Ratnani, I., Girgis, K. R., Nadaf, S., Fernández-Viña, M., & Carbone, D. P. (1996) · International Journal of Cancer · Cited by 63
Prognostic significance of cytokine modulation in non‐small cell lung cancer
Neuner, A., Schindel, M., Wildenberg, U., Muley, T., Lahm, H., & Fischer, J. R. (2002) · International Journal of Cancer · doi:10.1002/ijc.10604 · Cited by 61
Loss of HLA class‐I alleles, heavy chains and β2‐microglobulin in colorectal cancer
Kaklamanis, L., Gatter, K. C., Hill, A. B., Mortensen, N., Harris, A. L., Krausa, P., McMichael, A., Bodmer, J. G., & Bodmer, W. F. (1992) · International Journal of Cancer · doi:10.1002/ijc.2910510308 · Cited by 60
Méndez, R., Ruiz‐Cabello, F., Rodríguez, T., Campo, A. D., Paschen, A., Schadendorf, D., & Garrido, F. (2006) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-006-0166-2 · Cited by 60
Self-citationLoss of HLA molecules in B lymphomas is associated with an aggressive clinical course
Amiot, L., Onno, M., Lamy, T., Dauriac, C., Prisé, P. Y. L., Fauchet, R., & Drénou, B. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00631.x · Cited by 59
Vora, A., Rodgers, S., Parker, A., Start, R., Rees, R., & Murray, A. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.472 · Cited by 59
Höglund, M., Gorunova, L., Andrén‐Sandberg, Å., Dawiskiba, S., Mitelman, F., & Johansson, B. (1998) · Genes Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(199801)21:1<30::aid-gcc5>3.0.co;2-9 · Cited by 57
LOH at 6p21.3 region and HLA class altered phenotypes in bladder carcinomas
Maleno, I., Romero, J. M., Cabrera, T., Paco, L., Aptsiauri, N., Cózar, J. M., Tallada, M., López‐Nevot, M. Á., & Garrido, F. (2006) · Immunogenetics · doi:10.1007/s00251-006-0111-8 · Cited by 57
Self-citationGutierrez, J., López‐Nevot, M. Á., Cabrera, T., Oliva, R., Esquivias, J., Ruiz‐Cabello, F., & Garrido, F. (1987) · PubMed · Cited by 56
Self-citationAbril, E., Mendez, R. E., Garcia-Lora, A. M., Serrano, A., Cabrera, T., Garrido, F., & Ruiz‐Cabello, F. (1996) · Tissue Antigens · doi:10.1111/j.1399-0039.1996.tb02574.x · Cited by 55
Self-citationThe biological consequences of altered MHC expression on tumours
FESTENSTEIN, H. (1987) · British Medical Bulletin · doi:10.1093/oxfordjournals.bmb.a072172 · Cited by 55
Progress in manual breast examination
Hall, D. C., Goldstein, M. K., & Stein, G. H. (1977) · Cancer · doi:10.1002/1097-0142(197707)40:1<36::aid-cncr2820400108>3.0.co;2-7 · Cited by 54
Biological Implications of HLA‐DR Expression in Tumours
CABRERA, T., RUIZ‐CABELLO, F., & GARRIDO, F. (1995) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.1995.tb03584.x · Cited by 50
Self-citationA new β2 microglobulin mutation found in a melanoma tumor cell line
Pérez, B. F., Benitez, R., Fernández, M. A., Oliva, M. R., Soto, J. L., Serrano, S., López‐Nevot, M. Á., & Garrido, F. (1999) · Tissue Antigens · doi:10.1034/j.1399-0039.1999.530607.x · Cited by 49
Self-citationHigh frequency of altered HLA class I phenotypes in laryngeal carcinomas
Cabrera, T., Jose, S., Fernandez, M. A., Garrido, A., Esquivias, J., & Garrido, F. (2000) · Human Immunology · doi:10.1016/s0198-8859(00)00097-5 · Cited by 48
Self-citationReal, L. M., Jiménez, P., Kirkin, A. F., Serrano, A., Garcia-Lora, A. M., Cantón, J., Zeuthen, J., Garrido, F., & Ruiz‐Cabello, F. (2001) · Cancer Immunology Immunotherapy · doi:10.1007/s002620000154 · Cited by 48
Self-citationGarbi, N., Tanaka, S., van den Broek, M. F., Momburg, F., & Hämmerling, G. J. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00303.x · Cited by 46
HLA class I phenotype and genotype alterations in cervical carcinomas and derivative cell lines
Koopman, L. A., Mulder, A., Corver, W. E., Anholts, J. D. H., Giphart, M. J., Claas, F. H. J., & Fleuren, G. J. (1998) · Tissue Antigens · doi:10.1111/j.1399-0039.1998.tb03005.x · Cited by 45
Research works printed but not linked: 1
- Snell, 1952, Enhancement and inhibition of the growth of tumor homotransplants by pre‐treatment of the hosts with various preparations of normal and tumor tissue, J. Natl. Cancer Inst., 13, 719
Cited by
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
Havel, J. J., Chowell, D., & Chan, T. A. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0116-x · Cited by 2,286
Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy
Chowell, D., Morris, L. G. T., Grigg, C. M., Weber, J. K., Samstein, R. M., Makarov, V., Kuo, F., Kendall, S. M., Requena, D., Riaz, N., et al. (2018) · Science · doi:10.1126/science.aao4572 · Cited by 1,142
Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade
Hsu, J., Hodgins, J. J., Marathe, M., Nicolai, C. J., Bourgeois-Daigneault, M.-C., Trevino, T. N., Azimi, C. S., Scheer, A. K., Randolph, H. E., Thompson, T. W., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci99317 · Cited by 817
The HLA genomic loci map: expression, interaction, diversity and disease
Shiina, T., Hosomichi, K., Inoko, H., & Kulski, J. K. (2009) · Journal of Human Genetics · doi:10.1038/jhg.2008.5 · Cited by 782
Fu, Y., Sun, Y., Li, Y., Li, J., Rao, X., Chen, C., & Xu, A. (2011) · Genome Research · doi:10.1101/gr.115295.110 · Cited by 270
“This down-regulation could help the cancer cell to escape elimination by cytotoxic T cells, though complete loss of HLA class I molecules could also induce NK cell lysis (See reviews in Aptsiauri et al. [2007a]; Aptsiauri et al.”
Background
Metadata
- Authors
- Aptsiauri, N., Cabrera, T., Garcia‐Lora, A., Lopez‐Nevot, M. A., Ruiz‐Cabello, F., & Garrido, F.
- Affiliations
- Hospital Universitario Virgen de las Nieves (ES)
- Universidad de Granada (ES)
- Venue
- International Review of Cytology
- Publisher
- Elsevier
- Published
- 2007
- Volume
- 256
- Pages
- 139-189
- ISSN
- 0074-7696 (ISSN-L)
- OpenAlex
- W1493511814
- Cited by
- 145
- References
- 256
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 3 · 2023: 5 · 2022: 6 · 2021: 11 · 2020: 7 · 2019: 10 · 2018: 7 · 2017: 10 · 2016: 8 · 2015: 6 · 2014: 9 · 2013: 11 · 2012: 7
- FWCI
- 16.01
- Type
- book chapter
- Language
- en
- Open access
- closed
- Locations
- International review of cytology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Keywords
- MHC class I antigens, tumor immune evasion, MHC class I loss, tumor-associated antigens, cytotoxic T lymphocytes, natural killer cells, immune surveillance, transformed cells, tumor immunology
- MeSH terms
- Animals, Cell Transformation, Neoplastic, Humans, Immunologic Surveillance, Killer Cells, Natural, Models, Biological, Neoplasms, T-Lymphocytes, Histocompatibility Antigens Class I, Antigen Presentation, Disease Progression, Tumor Escape
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.